下一代癌症診斷全球市場規模、佔有率、成長分析、按應用、按癌症類型 - 產業預測，2024-2031 年

Global Next Generation Cancer Diagnostics Market Size, Share, Growth Analysis, By Application(Biomarker Development, CTC Analysis), By Cancer Type(Lung, Breast) - Industry Forecast 2024-2031

出版日期: 2024年03月09日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

下一代癌症診斷的全球市場規模預計在 2022 年達到 99 億美元，從 2023 年的 116.6 億美元成長到 2031 年的 432 億美元，預測期內（2024-2031 年）複合年成長率為 17.8%。預計將成長至5000萬美元。

傳統的實驗室測試正在被快速的照護現場測試所取代。這一轉變預計將有助於擴大市場，因為各種技術先進的產品預計將商業化，包括診斷套件、試劑和設備。隨著伴同性診斷的發展以提供增強和客製化的基因療法，預計在預測期內會有很高的市場成長機會。根據2021年全球癌症觀察站的數據，2020年全球報告了約83,000例何傑金氏淋巴瘤病例和544,000例非何傑金氏淋巴瘤病例。此外，2020 年報告了超過 474,000 例白血病病例和 176,000 例多發性骨髓瘤病例。據世界衛生組織 (WHO) 稱，癌症是全球第二大死因，每年估計導致 960 萬人死亡。隨著癌症盛行率的不斷增加，對更準確、更有效率的診斷設備的需求不斷增加。市場開拓得到了各種開發新癌症生物標記和診斷方法的行業公司的支持。癌症診斷能夠及早發現癌症並改善治療選擇。下一代癌症診斷將使疾病檢測更加準確且經濟實惠。研究人員不斷嘗試創造新的、微創的癌症診斷方法。每年報告的癌症新病例超過 375,000 例，病死率超過 44%。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東/非洲
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2021年）
主要市場參與者所採取的策略
關鍵成功策略
近期市集活動
主要企業市場佔有率（2021年）

主要企業簡介

Abbott Laboratories
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Danaher Corporation
Exact Sciences Corporation
F. Hoffmann-La Roche Ltd.
GE Healthcare
Grail, Inc.
Guardant Health, Inc.
Hologic, Inc.
Illumina, Inc.
Merck & Co., Inc.
Myriad Genetics, Inc.
NanoString Technologies, Inc.
Natera, Inc.
NeoGenomics, Inc.
Qiagen NV
Quest Diagnostics Incorporated
Siemens Healthineers AG
Sysmex Corporation
Thermo Fisher Scientific, Inc.
Veracyte, Inc.

簡介目錄

Product Code: SQMIG35A2226

Global Next Generation Cancer Diagnostics Market size was valued at USD 9.90 billion in 2022 and is poised to grow from USD 11.66 billion in 2023 to USD 43.25 billion by 2031, at a CAGR of 17.8% during the forecast period (2024-2031).

Traditional laboratory testing is being replaced by rapid point-of-care testing. This shift will aid in market expansion as it is anticipated that a wide range of technologically sophisticated goods, such as diagnostic kits, reagents, and devices, would be commercialized. Over the course of the forecast period, the market is expected to witness high-value growth opportunities as a result of the increased development of companion diagnostics for their use in providing enhanced and tailored genetic therapy. Global Cancer Observatory 2021 figures show that around 83,000 cases of Hodgkin lymphoma and 544,000 cases of non-Hodgkin lymphoma were reported worldwide in 2020. Furthermore, more than 474,000 cases of leukemia and more than 176,000 cases of multiple myeloma were reported in 2020. According to the World Health Organization, cancer is the second most prevalent cause of death globally, accounting for an estimated 9.6 million deaths annually. More accurate and efficient diagnostic instruments are becoming more and more necessary as the prevalence of cancer rises. Market expansion is being aided by the various industry players developing new cancer biomarkers and diagnostics. Cancer diagnostics enable early cancer detection, which improves treatment options. Next-generation cancer diagnosis makes illness detection more precise and reasonably priced. Researchers are constantly attempting to create new, minimally intrusive methods for cancer diagnosis. Annually, there are more than 375,000 new cases of cancer reported, with a fatality rate above 44%.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Next Generation Cancer Diagnostics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Next Generation Cancer Diagnostics Market Segmental Analysis

The cancer type, function, location, and application are the segments that make up the global market for next-generation cancer diagnostics. The market is divided into five application segments: proteomic analysis, ctc analysis, genetic analysis, epigenetic analysis, and biomarker development. The market is divided into lung, breast, colorectal, cervical, and other cancer types. The market is divided into segments based on function, including prognosis, cancer screening, companion diagnostics, therapeutic monitoring, and risk analysis. The market is divided into Latin America, Middle East and Africa, Asia Pacific, North America, and Europe.

Drivers of the Global Next Generation Cancer Diagnostics Market

The market for next-generation cancer diagnostics is expanding due to the growing need for tailored medications. Personalized medicine refers to the process of customizing a patient's course of care according to their genetic profile and other attributes. Patients who are most likely to benefit from individualized therapy can be identified with the use of next-generation cancer diagnostic techniques.

Restraints in the Global Next Generation Cancer Diagnostics Market

These difficulties stem from the vagueness of reimbursement guidelines and the glacial speed at which they are being developed. This ambiguity may hinder the uptake and application of these novel technologies, making it challenging for patients and healthcare professionals to defend the expenses of these examinations. There are significant differences in the reimbursement policies for next-generation cancer diagnostics between various nations, areas, and healthcare systems. It is not widely agreed upon how to pay for these new technologies, and in many cases, these policies are currently being created.

Market Trends of the Global Next Generation Cancer Diagnostics Market

For the diagnosis of cancer and the tracking of treatment, liquid biopsy assays have become a viable substitute for conventional tissue biopsy testing. To find cancer cells and other indicators, these tests analyze a patient's blood, urine, or other body fluids. Compared to conventional biopsy examinations, liquid biopsy procedures can yield more frequent and reliable results while requiring less financial and invasive resources. As a result, liquid biopsy tests are becoming more and more popular in the market, and numerous businesses have invested in their development.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Next Generation Cancer Diagnostics Market by Application

Market Overview
Biomarker Development
CTC Analysis
Proteomic Analysis
Epigenetic Analysis
Genetic Analysis

Global Next Generation Cancer Diagnostics Market by Cancer Type

Market Overview
Lung
Breast
Colorectal
Cervical
Others

Global Next Generation Cancer Diagnostics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grail, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NanoString Technologies, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NeoGenomics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Qiagen N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quest Diagnostics Incorporated
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Veracyte, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments